Kenta Biotech

About Kenta Biotech

Kenta Biotech is a biotechnology company dedicated to the discovery and development of novel, fully human monoclonal antibodies aimed at preventing and treating serious bacterial and viral infections in hospital settings. The company leverages advanced technology to generate and select these antibodies, harnessing the power of the human immune system to create highly effective therapeutic solutions. Kenta Biotech primarily serves hospitals and healthcare facilities that deal with severe nosocomial infections, which are infections acquired in hospitals and nursing homes. These infections affect an estimated 10% of all hospitalized patients and can lead to conditions such as urinary tract infections, wound infections, pneumonia, and bloodstream infections. The company's business model revolves around research and development (R&D) and the subsequent commercialization of its antibody therapies. Revenue is generated through the sale of these therapeutic antibodies to healthcare institutions and through potential partnerships or licensing agreements with larger pharmaceutical companies. Kenta Biotech's unique technology, combined with its focused scientific and clinical expertise, enables it to rapidly move innovative antibody therapies from the research phase to patients with high medical needs.